Press coverage about Valeritas Holdings (NASDAQ:VLRX) has trended somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Valeritas Holdings earned a coverage optimism score of 0.03 on Accern’s scale. Accern also gave media stories about the company an impact score of 45.7743521403545 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Several research firms have recently weighed in on VLRX. ValuEngine lowered shares of Valeritas Holdings from a “sell” rating to a “strong sell” rating in a research report on Wednesday, July 19th. Wedbush started coverage on shares of Valeritas Holdings in a research note on Monday, July 10th. They set an “outperform” rating and a $12.00 price objective for the company.
Valeritas Holdings (NASDAQ VLRX) traded up 2.0294% during mid-day trading on Monday, reaching $3.1221. 1,907 shares of the company’s stock were exchanged. The stock’s market cap is $21.36 million. The stock has a 50-day moving average price of $3.34 and a 200-day moving average price of $3.34. Valeritas Holdings has a 52 week low of $3.00 and a 52 week high of $6.25.
Valeritas Holdings (NASDAQ:VLRX) last posted its earnings results on Friday, August 11th. The company reported ($1.83) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.87) by $0.04. The company had revenue of $4.79 million for the quarter, compared to analyst estimates of $5.11 million. On average, analysts forecast that Valeritas Holdings will post ($8.60) earnings per share for the current year.
About Valeritas Holdings
Valeritas, Inc is a United States-based company, which is engaged in developing and commercializing treatment solutions that contribute to clinical outcomes for patients. The Company’s portfolio includes V-Go disposable insulin delivery device, which is distributed through retail pharmacy. Its V-Go delivers insulin at a continuous preset basal rate and bolus dosing for adults with Type 2 diabetes requiring insulin.
Receive News & Ratings for Valeritas Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeritas Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.